Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome

NCT ID: NCT04451616

Last Updated: 2020-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-03

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is planned to be conducted on 40 adults with metabolic syndrome. As a control, it is planned to recruit 40 adults without metabolic syndrome. From all participants fasting venous blood samples, urine samples and hair samples will be collected. Next, serum progranulin and serum FAM19A5 protein concentrations will be determined in both groups. Also, serum concentration of leptin, vascular endothelial growth factor (VEGF), insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Serum, hair and urine mineral content will be determined. In whole blood genetic analyses will be performed in order to detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and genes associated with the body's mineral metabolism. Also, body composition analysis, blood pressure measurement, pulse measurement, blood oxygen saturation measurement and nutritional interview will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nutrition Disorders Hypertension Dyslipidemias Glucose Intolerance Glucose Metabolism Disorders Obesity Overweight and Obesity Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A - study group - patients with metabolic syndrome

Patients with metabolic syndrome will be included.

Procedures:

1. blood sample collection
2. hair sample collection
3. urine sample collection
4. body composition analysis
5. questionnaires
6. blood pressure, pulse and blood oxygen saturation measurement

Blood sample collection

Intervention Type DIAGNOSTIC_TEST

Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.

Hair sample collection

Intervention Type DIAGNOSTIC_TEST

Hair sample collection will be performed. Hair mineral analysis will be performed.

Urine sample collection

Intervention Type DIAGNOSTIC_TEST

Urine sample collection will be performed. Urine mineral analysis will be performed.

Body composition analysis

Intervention Type DIAGNOSTIC_TEST

Body composition analysis with the use of electric bioimpedance will be performed.

Questionnaires

Intervention Type DIAGNOSTIC_TEST

Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.

Blood pressure, pulse and blood oxygen saturation measurement

Intervention Type DIAGNOSTIC_TEST

Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.

Group B - control group - patients without metabolic syndrome

Patients without metabolic syndrome will be included.

1. blood sample collection
2. hair sample collection
3. urine sample collection
4. body composition analysis
5. questionnaires
6. blood pressure, pulse and blood oxygen saturation measurement

Blood sample collection

Intervention Type DIAGNOSTIC_TEST

Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.

Hair sample collection

Intervention Type DIAGNOSTIC_TEST

Hair sample collection will be performed. Hair mineral analysis will be performed.

Urine sample collection

Intervention Type DIAGNOSTIC_TEST

Urine sample collection will be performed. Urine mineral analysis will be performed.

Body composition analysis

Intervention Type DIAGNOSTIC_TEST

Body composition analysis with the use of electric bioimpedance will be performed.

Questionnaires

Intervention Type DIAGNOSTIC_TEST

Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.

Blood pressure, pulse and blood oxygen saturation measurement

Intervention Type DIAGNOSTIC_TEST

Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample collection

Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.

Intervention Type DIAGNOSTIC_TEST

Hair sample collection

Hair sample collection will be performed. Hair mineral analysis will be performed.

Intervention Type DIAGNOSTIC_TEST

Urine sample collection

Urine sample collection will be performed. Urine mineral analysis will be performed.

Intervention Type DIAGNOSTIC_TEST

Body composition analysis

Body composition analysis with the use of electric bioimpedance will be performed.

Intervention Type DIAGNOSTIC_TEST

Questionnaires

Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.

Intervention Type DIAGNOSTIC_TEST

Blood pressure, pulse and blood oxygen saturation measurement

Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* written and informed consent of the participant to participate in the study;
* age 18-99;
* meeting at least three of the following five metabolic syndrome criteria:

* waist circumference ≥80 cm in women and ≥94 cm in men;
* serum triglycerides\> 150 mg / dl (1.7 mmol / l) or treatment of hypertriglyceridemia;
* HDL serum concentration \<50 mg / dl (1.3 mmol / l) - in women and \<40 mg / dl (1.0 mmol / l) - in men or treatment of this lipid disorder;
* systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg, or treatment of previously diagnosed hypertension;
* fasting plasma glucose ≥100 mg / dl (5.6 mmol / l) or pharmacological treatment of type 2 diabetes.

Exclusion Criteria

* secondary form obesity,
* substitution of progranulin or / and FAM19A5 protein,
* weight reduction above 5% of baseline body weight in the last 3 months preceding recruitment,
* liposuction and / or other fat reduction treatments,
* pacemaker, cardioverter / defibrillator,
* condition after stroke,
* Alzheimer's disease,
* fronto-temporal dementia,
* occurrence of other neurodegenerative diseases,
* occurrence of significant neurological disorders,
* occurrence of inflammatory autoimmune diseases,
* lysosomal storage diseases,
* clinically significant abnormal liver, kidney or thyroid function;
* acute or clinically significant inflammatory process in the respiratory, digestive, genitourinary tracts,
* connective tissue diseases or arthritis;
* active cancer,
* addiction to alcohol or drugs;
* pregnancy or childbirth during recruitment or 3 months before recruitment;
* current lactation or lactation within 3 months before recruitment;
* and / or any other condition which, according to researchers, would cause that participation would not be in the patient's best interest or could limit the credibility of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Poznan University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Damian Skrypnik, MD; PhD

Role: STUDY_CHAIR

Poznan University of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences

Poznan, Wielkopolska, Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Damian Skrypnik, MD, PhD

Role: CONTACT

+48 618549742

Agnieszka Wesołek, licentiate

Role: CONTACT

+48 618549742

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Damian Skrypnik, MD, PhD

Role: primary

+48798394812

Paweł Bogdański, Prof.

Role: backup

+48502335001

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

353/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.